Form 4: Aardvark Therapeutics CFO Nelson Sun Reports Stock Transactions
SEC Form 4 Filing
CFO Nelson Sun reports acquisition of Aardvark Therapeutics common stock and conversion of Series C Convertible Preferred Stock.
Summary
- On February 14, 2025, Nelson Sun, the CFO of Aardvark Therapeutics, reported acquiring 7,001 shares of Common Stock through conversion of Series C Convertible Preferred Stock.
- Sun also acquired 10,000 shares of Common Stock at a price of $16 per share.
- Following these transactions, Sun beneficially owns 99,484 shares of Aardvark Therapeutics Common Stock directly.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, reflecting standard insider trading activity. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions, which are common after a company's initial public offering.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of Common Stock acquisition and Series C Convertible Preferred Stock conversion |
| 02/19/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.